Chinese medicine body joins list of WHO observers

Published: 27-Mar-2015
Regulatory

Will give traditional Chinese medicine (TCM) a voice in international health affairs


The World Federation of Chinese Medicine Societies (WFCMS) has welcomed its establishment of an official relationship with the World Health Organization (WHO), saying it will give traditional Chinese medicine (TCM) a voice in international health affairs.

The WFCMS is now listed on the 202-strong list of non-governmental organisations with official relations with the WHO.

'Participation in international health affairs can help promote the development of TCM overseas, making it part of medical and healthcare systems of other countries,' said She Jing, Chair of the Beijing-based Federation.

The official recognition will enable the WFCMS to attend various WHO meetings and therefore 'will have a say in global decision-making on major health issues,' said Li Zhenji, Vice-Chair of the WFCMS.

She said the WFCMS would offer technical support to the WHO and cooperate with other NGOs to promote TCM.

Other listed NGOs include the International Federation of Pharmaceutical Manufacturers and Associations; the International Pharmaceutical Federation; and Alzheimer's Disease International.

  • Companies:
  • World Health Organization
  • World Federation of Chinese Medicine Societies
See more

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

Read more
China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further
  5. AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial
Regulatory

WHO proposes central registry on human genome editing research

On the heels of the Chinese CRISPR scandal, stakeholders in the genome editing industry will be consulted to create standards for future research
Regulatory

Annex 1 harmonisation moves a step closer

Revision to Annex 1 on the manufacturing of sterile medicinal products of the PIC/S – EU GMP Guide goes out for joint stakeholder consultation
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

EU considers endocrine disrupter controls

It has long been known that pharmaceutical residues can become hormone-affecting ‘endocrine disrupters’ when released into the environment and future controls are likely – but how will the legislators tackle the issue? Manufacturing Chemist reports
Regulatory

India Pharmacopoeia Commission joins WHO network

India has set up 179 centres to monitor adverse drug reactions across the country
Regulatory

European Commission, EMA and WHO step up co-operation to protect global public health

New working arrangement will allow timely sharing of non-public information
Regulatory

Vietnamese national regulatory authority meets international standards for vaccine regulation

The World Health Organisation has formally certified that Vietnam has a fully equipped national regulatory system that ensures the safety and efficacy of vaccines produced and used in the country
Subscribe now